drugset / Trial / NCT05110976

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976 ↗

Phase 1 Completed 170 enrolled AstraZeneca
RandomizedSequentialQuadruple-blindOther

Summary

This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)

Timeline

Start
2021-12-16
Primary completion
2023-08-02
Completion
2023-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8630 Unknown — Inhaled

Indications